Back to search

University of British Columbia

Development and validation of a new preclinical analgesic assay

Abstract

dc:description

Current preclinical analgesic assays suffer from major weaknesses that hamper the discovery of new drugs. This thesis describes the development of a new mouse assay, the Hypertonic Saline Analgesia Assay (HSAA). Chapter 1 provides an overview for current preclinical analgesic assays and discusses their strengths and weaknesses. It also discusses the impact of sex, strain, and circadian rhythm on nociception and antinociception. Chapter 2 describes the development of the assay. We evaluated hypertonic saline (HS) as a nociceptive agent, its optimal concentration, the responses, and the optimal time for evaluation. We also assessed sex related differences and tissue damage. Chapter 3 describes the validation of the assay. Analgesics known to be effective clinically were assayed to establish the validity of the HSAA. HSAA demonstrated that responses were attenuated by a range of clinical analgesics, produces minimal tissue damage and has lower variability compared to other assays. Chapter 4 examines the refinement of the assay. We determined the effects of repeated testing, strain, sex, and diurnal rhythm on the reproducibility of HSAA. The absence of tissue damage raised the possibility of repeated testing in a mouse to reduce the number of animals. The antinociceptive action of morphine was unchanged when HSAA was used at different times in the same hind paw of a mouse. No histological damage was observed following multiple injections of HS. Repeated testing in the same mouse reduces both the number of animals required and the variance of the results. Initial development and validation were performed with CD-1 mice. To evaluate the widespread utility of HSAA, we evaluated its ability to detect analgesics in another commonly used murine strain, C57BL/6. HSAA detected the dose-dependent attenuation of responses by morphine in C57BL/6 which was equivalent to responses found with CD-1 mice. Additionally, female mice were demonstrated to have greater response than males. The diurnal cycle had little effect. In conclusion, the HSAA rapidly detects standard analgesics and is reproducible within an animal and between strains. This assay minimizes tissue damage and the number of animals required. HSAA is a useful addition to the armamentarium of preclinical analgesic assays.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy - PhD
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Pharmacology and Therapeutics
Grantor dc:publisher
University of British Columbia
Year dc:date
2018

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Asiri, Yahya I. A.

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/67109

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Asiri, Yahya I. A.. Development and validation of a new preclinical analgesic assay. doctoral thesis, University of British Columbia, 2018. http://hdl.handle.net/2429/67109